

# RT-LAMP has high accuracy for detecting SARS-CoV-2 in saliva and naso/oropharyngeal swabs from asymptomatic and symptomatic individuals

**Short title:** RT-LAMP for detecting SARS-CoV-2 in saliva and naso/oropharyngeal swabs

†Stephen P. Kidd<sup>1,2</sup>, †Daniel Burns<sup>1,3</sup>, Bryony Armson<sup>1,2,4</sup>, Andrew D. Beggs<sup>5</sup>, Emma L. A. Howson<sup>6</sup>, Anthony Williams<sup>7</sup>, Gemma Snell<sup>7</sup>, Emma L. Wise<sup>1,8</sup>, Alice Goring<sup>1</sup>, Zoe Vincent-Mistiaen<sup>9</sup>, Seden Grippon<sup>1</sup>, Jason Sawyer<sup>10</sup>, Claire Cassar<sup>10</sup>, David Cross<sup>10</sup>, Thomas Lewis<sup>10</sup>, Scott M. Reid<sup>10</sup>, Samantha Rivers<sup>10</sup>, Joe James<sup>10</sup>, Paul Skinner<sup>10</sup>, Ashley Banyard<sup>10</sup>, Kerrie Davies<sup>11</sup>, Anetta Ptasińska<sup>5</sup>, Celina Whalley<sup>5</sup>, Jack Ferguson<sup>5</sup>, Claire Bryer<sup>5</sup>, Charlie Poxon<sup>5</sup>, Andrew Bosworth<sup>5</sup>, Michael Kidd<sup>5,12</sup>, Alex Richter<sup>13</sup>, Jane Burton<sup>14</sup>, Hannah Love<sup>14</sup>, Sarah Fouch<sup>1</sup>, Claire Tillyer<sup>1</sup>, Amy Sowood<sup>1</sup>, Helen Patrick<sup>1</sup>, Nathan Moore<sup>1</sup>, <sup>‡</sup>Michael Andreou<sup>15</sup>, <sup>‡</sup>Nick Morant<sup>16</sup>, Rebecca Houghton<sup>1</sup>, Joe Parker<sup>17</sup>, Joanne Slater-Jefferies<sup>17</sup>, Ian Brown<sup>10</sup>, Cosima Gretton<sup>2</sup>, Zandra Deans<sup>2</sup>, Deborah Porter<sup>2</sup>, Nicholas J. Cortes<sup>1,9</sup>, Angela Douglas<sup>2</sup>, Sue L. Hill<sup>2</sup>, \*Keith M. Godfrey<sup>18,19</sup>, \*Veronica L. Fowler<sup>1,2</sup>

<sup>1</sup>Hampshire Hospitals NHS Foundation Trust, Department of Microbiology, Basingstoke and North Hants Hospital, Basingstoke, UK

<sup>2</sup>NHS Test and Trace Programme, Department of Health and Social Care, UK

<sup>3</sup>School of Electronics and Computer Science, University of Southampton, UK

<sup>4</sup>vHive, School of Veterinary Medicine, University of Surrey, Guildford, UK

<sup>5</sup>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>6</sup>The Pirbright Institute, Ash Road, Pirbright, Woking, UK

<sup>7</sup>University of Southampton & Division of Specialist Medicine, University Hospital Southampton, UK

<sup>8</sup>School of Biosciences and Medicine, University of Surrey, Guildford, UK

<sup>9</sup>Gibraltar Health Authority, Gibraltar, UK

<sup>10</sup>Animal and Plant Health Agency, New Haw, Addlestone, Surrey, UK

<sup>11</sup>Leeds Teaching Hospitals NHS Trust and University of Leeds, UK

<sup>12</sup>Public Health West Midlands Laboratory, Birmingham, UK

<sup>13</sup>Institute of Immunology and Immunotherapy, University of Birmingham, UK

<sup>14</sup>High Containment Microbiology, National Infection Service, Public Health England, Porton Down, UK

<sup>15</sup>OptiSense Limited, Horsham, West Sussex, UK

<sup>16</sup>GeneSys Biotech Limited, Camberley, Surrey, UK

<sup>17</sup>National Biofilms Innovation Centre, University of Southampton, UK

<sup>18</sup>NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital, UK

<sup>19</sup>MRC Lifecourse Epidemiology Centre, University of Southampton, UK

†Denotes co-first authorship; \*Senior author; \*Corresponding author

<sup>‡</sup>Supplied reagents free of charge but did not assist in study design or data analysis.

Corresponding author: Keith M. Godfrey, [kmg@soton.ac.uk](mailto:kmg@soton.ac.uk), MRC Lifecourse Epidemiology Centre (University of Southampton), University Hospital Southampton, Mailpoint 95, Southampton SO16 6YD, UK.

Tables: 5, Figures: 4

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Running title: Saliva SARS-CoV-2 detection by RT-LAMP

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
  
57  
58  
59  
  
60  
61

Grant numbers and sources of support: OptiGene Ltd. supplied reagents free of charge for this study. This work was partially funded by a UK Department of Health and Social Care award to the University of Southampton (Grant Reference Number 2020/032 (Feasibility study for city-wide testing using saliva based LAMP testing)). The views expressed are those of the authors and not necessarily those of the Department of Health and Social Care. KMG is supported by the UK Medical Research Council (MC\_UU\_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515- 318 10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)) and the British Heart Foundation (RG/15/17/3174). For part of this project, Emma Howson was on secondment at GeneSys Biotech Ltd., which was part funded by The Pirbright Institute Flexible Talent Mobility Account (FTMA) under BBSRC grant BB/S507945/1. ADB is currently supported by a Cancer Research UK Advanced Clinician Scientist award (C31641/A23923) and his laboratory is supported by CRUK Centre Birmingham (C17422/A25154) and the Birmingham Experimental Cancer Medicine Centre (C11497/A25127). VLF, SPK, BA and ZD were on secondment to the Department of Health and Social Care for a period during this study. APHA laboratory activities and expertise was supported by both the Safe and Certain project APHACSKL0085 and Defra project APHANSOM0416.

Disclosures: MA is an employee of OptiSense Limited, and NM an employee of GeneSys Biotech Limited; neither had any role in study design or data analysis. KMG is part of an academic consortium that has received research funding from Abbott Nutrition, Nestec, BenevolentAI Bio Ltd. and Danone.

## 62 Abstract

63 Previous studies have described RT-LAMP methodology for the rapid detection of SARS-CoV-2 in  
 64 nasopharyngeal (NP) and oropharyngeal (OP) swab and saliva samples. This study describes the validation  
 65 of an improved sample preparation method for extraction free RT-LAMP and defines the clinical  
 66 performance of four different RT-LAMP assay formats for detection of SARS-CoV-2 within a multisite  
 67 clinical evaluation. Direct RT-LAMP was performed on 559 swabs and 86,760 saliva samples and RNA RT-  
 68 LAMP on extracted RNA from 12,619 swabs and 12,521 saliva from asymptomatic and symptomatic  
 69 individuals across healthcare and community settings. For Direct RT-LAMP, overall diagnostic sensitivity  
 70 (DSe) of 70.35% (95% CI 63.48-76.60%) on swabs and 84.62% (79.50-88.88%) on saliva was observed, with  
 71 diagnostic specificity (DSp) of 100% (98.98-100.00%) on swabs and 100% (99.72-100.00%) on saliva when  
 72 compared to RT-qPCR; analysing samples with RT-qPCR *ORF1ab* C<sub>T</sub> values of  $\leq 25$  and  $\leq 33$ , DSe of 100%  
 73 (96.34-100%) and 77.78% (70.99-83.62%) for swabs were observed, and 99.01% (94.61-99.97%) and  
 74 87.61% (82.69-91.54%) for saliva, respectively. For RNA RT-LAMP, overall DSe and DSp were 96.06%  
 75 (92.88-98.12%) and 99.99% (99.95-100%) for swabs, and 80.65% (73.54-86.54%) and 99.99% (99.95-  
 76 100%) for saliva, respectively. These findings demonstrate that RT-LAMP is applicable to a variety of use-  
 77 cases, including frequent, interval-based testing of saliva with Direct RT-LAMP from asymptomatic  
 78 individuals that may otherwise be missed using symptomatic testing alone.

79

80

## Introduction

Rapid diagnostic testing to identify and isolate symptomatic and asymptomatic individuals potentially transmitting infectious viral pathogens is an essential requirement of any pandemic response. The novel *betacoronavirus*, SARS-CoV-2, initially identified after an outbreak of viral pneumonia in Wuhan, China in December 2019<sup>1</sup>, has rapidly spread throughout the world, causing over 223 million confirmed cases and over 4.6 million deaths (<https://coronavirus.jhu.edu/> - September 10, 2021).

Conventional diagnostics for SARS-CoV-2 consist of RNA enrichment followed by reverse-transcriptase quantitative real-time PCR (RT-qPCR) against one or more viral gene targets<sup>2</sup>. However, this methodology requires sample inactivation, RNA extraction and RT-qPCR thermal cycling, meaning that the time from sample-to-result can often be several hours, and requires centralised equipment and personnel trained in Good Laboratory Practice to perform testing.

The utility of reverse-transcriptase loop mediated isothermal amplification (RT-LAMP) for the detection of SARS-CoV-2 both from extracted RNA (RNA RT-LAMP) and directly from NP/OP swabs (Direct RT-LAMP)<sup>3</sup> has previously been shown. RT-LAMP utilises a rapid and stable DNA polymerase that amplifies target nucleic acids at a constant temperature. This removes the requirement for conventional thermal cycling allowing RT-LAMP reactions to be performed in shorter reaction times using less sophisticated platforms.

In a study of 196 clinical samples<sup>3</sup>, testing of RNA extracted from NP/OP swabs collected into viral transport media (VTM) using RNA RT-LAMP demonstrated a diagnostic sensitivity (DSe) of 97% and a diagnostic specificity (DSp) of 99% in comparison to RT-qPCR of the ORF1ab region of SARS-CoV-2. For Direct RT-LAMP on crude swab samples, the DSe and DSp were 67% and 97%, respectively. When a cycle threshold (C<sub>T</sub>) cut-off for RT-qPCR of < 25 was considered, reflecting the increased likelihood of detecting viral RNA from active viral replication, the DSe of Direct RT-LAMP increased to 100%<sup>3</sup>.

However, the collection of a swab sample is invasive and during the time of the pandemic there have been considerable shortages in swab supplies. Exploring the use of alternative sample types that are both easy to collect and more comfortable from a sampling perspective<sup>4,5,6</sup> is desirable particularly when repeat sampling is performed<sup>7,8,9</sup>. Saliva presents an ideal bio-fluid that fulfils both these objectives and previous studies have shown that SARS-CoV-2 is readily detectable in such a sample type<sup>10,11,12-18</sup>. To improve the diagnostic sensitivity of previously described saliva Direct RT-LAMP<sup>3</sup>, optimisation of saliva preparation for the detection of SARS-CoV-2 was undertaken utilising a cohort of 3100 saliva samples from an asymptomatic population<sup>19</sup> of healthcare workers; where saliva was diluted 1:1 in Mucolyse™, followed by a 1 in 10 dilution in 10% (w/v) Chelex® 100 Resin ending with a 98°C heat step prior to RT-LAMP which resulted in optimal sensitivity and specificity.

Despite the benefits of this optimisation, the protocol added additional steps and reagents which increased chance for user error and made the automation of the process more challenging. This study therefore aimed to investigate a simpler process using a novel reagent, RapiLyze (OptiGene Ltd, Camberley, UK), which is a sample dilution buffer, followed by a two-minute heat-step. This novel sample preparation method was evaluated in combination with Direct RT-LAMP using samples collected from symptomatic National Health Service (NHS) patients and symptomatic and asymptomatic healthcare staff.

## Methods

### Ethical statement

All relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. National Research Ethics Service Committee West Midlands - South Birmingham 2002/201 Amendment Number 4. All necessary written participant consent has been obtained and the appropriate institutional forms have been archived.

### Testing sites

The OptiGene Ltd. SARS-CoV-2 RT-LAMP assay was evaluated in nine sites, comprising Basingstoke and North Hampshire Hospital & Royal Hampshire County Hospital, Hampshire Hospitals NHS Foundation Trust; University Hospital Southampton; Animal and Plant Health Agency/MRC Lifecourse Epidemiology Unit (University of Southampton); Public Health Lab Manchester/CMFT; Leeds Teaching Hospitals NHS Trust; University Hospitals Birmingham (UHB) NHS Foundation Trust/Institute of Cancer & Genomic Science University of Birmingham; High Containment Microbiology, National Infection Service, Public Health England, Porton Down and Public Health University Laboratory, Gibraltar Health Authority, Gibraltar, UK.

### Clinical samples

Nasopharyngeal (NP) and oropharyngeal (OP) swabs were collected from asymptomatic and symptomatic individuals and placed in viral transport media (VTM).

Drooled saliva samples were collected at the start of the day; prior to eating, drinking, teeth brushing, or using a mouthwash. Saliva was transferred into the specimen pot directly or via a clean teaspoon, according to a standardised protocol. Samples from UHB deposited saliva straight into the collection pot.

### Log reduction of SARS-CoV-2 for the heat and lysis steps used independently and sequentially

We determined the viral inactivation kinetics of the best sample preparation condition(s), evaluating the effect of the heat and lysis steps on the viral inactivation of SARS-CoV-2 as determined by infectivity assays. All inactivation experiments were conducted under Containment Level 3 Containment and as such

were undertaken at APHA. Heat inactivation experiments were conducted utilising high titre live SARS-CoV-2 virus spiked into pools of saliva collected from APHA staff or in tissue culture supernatant (TCSN). Early experiments demonstrated that saliva had a high toxicity for tissue culture cells, even after heat inactivation demonstrating that toxicity was likely not enzymatic. As such further inactivation was undertaken on live virus TCSN. Comparison was also undertaken of Betapropiolactone (BPL) inactivated virus and live virus.

## **RNA extraction**

RNA was extracted using a range of different methods available at each participating site:

### *Maxwell® RSC Viral Total Nucleic Acid Purification Kit*

In a class 1 microbiological safety cabinet (MSC) within a containment level 3 laboratory, 200 µl of sample was added to 223 µl of prepared lysis solution (including 5 µl per reaction of Genesig® Easy RNA Internal extraction control, Primerdesign Ltd, Chandler's Ford, UK). Samples were then inactivated for 10 minutes at room temperature within the MSC and 10 minutes at 56°C on a heat block before automated RNA extraction using a Maxwell® RSC48 Instrument (Promega UK Ltd., Southampton, UK). RNA was eluted in 50 µl of nuclease-free water (NFW).

### *MagMAX™CORE Nucleic acid 140 purification kit*

10 µl of sample (diluted in 190µl DEPC treated water) was added to 700 µl of prepared lysis solution. Samples were then inactivated for 10 minutes at room temperature within the safety cabinet before automated RNA extraction using a Kingfisher Flex (Thermo Fisher, Basingstoke, UK). RNA was eluted in 90 µl of NFW.

### *Roche FLOW system*

RNA extraction was carried out on a MagNA Pure 96 (MP96) extraction robot using the MagNA Pure 96 DNA and Viral Nucleic Acid Small Volume kit (Roche, Basel, Switzerland) and the Pathogen 200 universal protocol v4.0.

### *Qiagen QIASymphony*

RNA extraction was carried out using the QIASymphony Virus/Bacteria Mini Kit (Qiagen, Hilden, Germany) by the CellFree200 Default IC protocol with a 60 µl extract elution volume.

## **SARS-CoV-2 Real-Time RT-qPCR**

RNA was analysed using a range of different methods available at each site:

### *CerTest VIASURE SARS-CoV-2 real time qPCR assay*

Single step RT-qPCR against the *ORF1ab* region and *N1* gene target of SARS-CoV-2 was carried out using the CerTest VIASURE SARS-CoV-2 real time PCR kit (CerTest Biotech SL, Zaragoza, Spain) according to manufacturer's instructions for use (IFU) on either the Thermo Fisher QuantStudio 5 or BioMolecular Systems (Queensland, Australia) MIC instruments, using 5 µl of extracted RNA per reaction. RNA extracted using the Maxwell® RSC Viral Total Nucleic Acid Purification Kit was analysed using this assay.

#### COVID-19 genesig® Real-Time qPCR assay

Single step RT-qPCR against the *ORF1ab* region of SARS-CoV-2 was carried out using the COVID-19 genesig® Real-Time PCR assay real time PCR assay (Primerdesign Ltd, Chandler's Ford, UK) according to manufacturer's instructions for use (IFU) on BioMolecular Systems MIC instruments, using 5 µl of extracted RNA per reaction. RNA extracted using the Maxwell® RSC Viral Total Nucleic Acid Purification Kit was analysed using this assay.

#### Corman et al. Real-Time qPCR assay

Single step RT-qPCR against the *E* gene target of SARS-CoV-2 was carried out with the Corman et al.<sup>2</sup> primers using the AgPath-ID™ PCR kit (Thermo Fisher) according to manufacturer's instructions for use (IFU) on an Aria qPCR Cycler (Agilent, Cheshire, UK) and results analysed using the Agilent AriaMX 1.5 software, using 5 µl of extracted RNA per reaction. RNA extracted using the MagMAX™CORE Nucleic acid purification kit were analysed using this assay.

RT-qPCR was carried out on an Applied Biosystems Fast 7500 PCR thermocycler in standard run mode using the SARS-CoV-2 *E* gene Sarbeco assay using MS2 as an internal extraction control and aliquots of SARS-CoV-2/England/2/2020 as a positive control. The master mix comprised *E*- gene F and R primers and TM-P (400 nM, 400 nM and 200 nM final concentration respectively), MS2 primers and TM probe (20 nM, 20 nM and 40 nM final concentration respectively), 4 x TaqMan® Fast Virus 1-Step Master Mix made up with molecular-grade nuclease free water (Ambion) to a final volume of 15 µl. 5 µl of AVE buffer extract was used as a template and added to the 15 µl mastermix. Cycling conditions were 55°C for 10 min, followed by 94°C for 3 min and 45 cycles of 95°C for 15 s and 58°C for 30 s.

#### SARS-CoV-2 (2019-nCoV) CDC qPCR Probe Assay

Single step RT-qPCR against the *N1* and *N2* gene targets of SARS-CoV-2 was carried out using integrated design technologies kit (IDT; Catalogue number: 10006606) according to manufacturer's instructions for use (IFU) on either a LC480 II or ABI 7500 FAST instrument. RNA extracted on Qiagen QIAasympy and the Roche FLOW system were analysed using this RT-qPCR assay.



## 206 RT-LAMP

207 RT-LAMP assays were performed using OptiGene Ltd. COVID-19\_RT-LAMP kits, as described previously<sup>3</sup>,  
 208 with the following modifications. The COVID-19\_RNA RT-LAMP KIT-500 kit was used for RNA RT-LAMP  
 209 and the COVID-19\_Direct PLUS RT-LAMP KIT-500 was used for Direct RT-LAMP directly on  
 210 oropharyngeal/nasopharyngeal swabs or saliva samples. The COVID-19\_Direct PLUS RT-LAMP KIT-500 kit  
 211 also includes a sample preparation buffer, RapiLyze. For RNA RT-LAMP 5 µl of extracted RNA was added  
 212 to the reaction. For the Direct PLUS RT-LAMP, 50 µl sample (swab VTM or neat saliva) was added to 50 µl  
 213 RapiLyze, vortexed and placed in a dry heat block pre-heated to 98°C for 2 mins. 5 µl of the treated sample  
 214 was added to each reaction.

215 The anneal temperature (Ta) that confirmed a positive result for Direct RT-LAMP was modified to 81.5°C  
 216 and 85.99°C because of the effect of RapiLyze buffer on the reaction.

217

## 218 SARS-CoV-2 viral culture of clinical samples across a C<sub>T</sub> range

219 For culture, 100 µl and 100 µl of a 1 in 10 dilution of samples 1-6 (predicted lower C<sub>T</sub> values) and 100 µl  
 220 samples 7-26 (with higher predicted C<sub>T</sub> values) were added to a 25 cm<sup>2</sup> flasks containing 80% confluent  
 221 Vero E6 cells and allowed to adsorb for 1 hour. Five ml of Minimum Essential Medium (MEM) (Gibco) +  
 222 HEPES (Gibco, Thermo Fisher, Basingstoke, UK) + 4% foetal calf serum FCS (Sigma) + 1 x antibiotic-  
 223 antimycotic (Gibco) was added to each flask and incubated for 1 week at 37°C. Two negative control flasks  
 224 to which 100 µl MEM + 4% FCS was added in place of sample, were set up in parallel. Cultures were  
 225 checked visually for cytopathic effect (CPE). Where CPE was not observed after 1 week, 500 µl of  
 226 supernatant was passed into a fresh flask containing Vero E6 cells for a further two passages. At the  
 227 beginning and end of each passage 140 µl of supernatant was collected for SARS-CoV-2 RT-qPCR as  
 228 described before.

229 To determine the sensitivity of the isolation method for SARS-CoV-2 from clinical samples, a virus stock  
 230 titred by plaque assay (HCM/V/53), a passage 3 working bank grown from SARS-CoV-2 Strain England 2,  
 231 from Public Health England, was diluted in MEM to give virus dilutions containing 1000, 100, 10, 1, 0.1  
 232 and 0.01 PFU. The virus was added to duplicate flasks containing Vero E6 cells and AVL. After 72 hours of  
 233 incubation flasks were checked for CPE, and for those where CPE was observed the supernatant was  
 234 collected for RT-qPCR. Any flasks not showing CPE after 7 days were passed on to fresh cells and  
 235 resampled as described above.



## Data analysis

Overall diagnostic sensitivity and specificity (including 95% Clopper-Pearson confidence intervals) were calculated by the aggregation of individual site data for each method (RNA and Direct RT-LAMP) for each sample type (swabs and saliva). To demonstrate the effectiveness of detecting samples with higher viral load, confusion matrices are quoted where the threshold for *positive* sample inclusion varies, i.e., for  $C_T \leq 25$ , only positive samples with  $C_T \leq 25$  are included.

To account for site heterogeneity, a bivariate meta-analysis model is additionally applied at the site level to produce a summary of sensitivity and specificity for each method and sample type<sup>20</sup>. Within-study variability for sensitivity  $\rho_{se,i}$  and specificity  $\rho_{sp,i}$  are assumed to follow independent binomial distributions

$$x_{se,i} \sim B(n_{se,i}, \rho_{se,i}), \quad x_{sp,i} \sim B(n_{sp,i}, \rho_{sp,i})$$

where  $x_{se,i}, x_{sp,i}$  represent the number testing positive for site  $i$  respectively, and  $n_{se,i}, n_{sp,i}$  represent the number testing positive and negative by RT-qPCR for site  $i$  respectively. The between-study heterogeneity is represented by a bivariate normal distribution for the logit-transformed sensitivity  $\mu_{se,i}$  and specificity  $\mu_{sp,i}$

$$\begin{pmatrix} \mu_{se,i} \\ \mu_{sp,i} \end{pmatrix} \sim N \left( \begin{pmatrix} \mu_{se} \\ \mu_{sp} \end{pmatrix}, \begin{pmatrix} \sigma_{se}^2 & \sigma_{se,sp} \\ \sigma_{se,sp} & \sigma_{sp}^2 \end{pmatrix} \right)$$

where  $\mu_{se}, \mu_{sp}$  represent the expected logit sensitivity and specificity,  $\sigma_{se}^2, \sigma_{sp}^2$  represent the between-study variance in the logit sensitivity and specificity, and  $\sigma_{se,sp}$  represents the covariance between the logit sensitivity and specificity. For Direct RT-LAMP, we fit a univariate normal distribution for the logit-transformed sensitivity only, due to the absence of false positives across all sites.

In addition, the sensitivity as a function of viral load was assessed for RNA RT-LAMP and Direct RT-LAMP on both swab and saliva samples. This was performed through the conversion of each sample  $C_T$  value to viral load in gene copies/ml for all sample sets. As the relationship between  $C_T$  value and viral load varied according to the RT-qPCR method used; a dilution series was utilised for each method to standardise these values for two of the four aforementioned RT-qPCR methods (CerTest VIASURE SARS-CoV-2 real time PCR kit, and Corman *et al* RT-qPCR assay *E* gene), which was used for testing 100% of the swab samples, 90% of the saliva samples used for Direct RT-LAMP, and 83% of the saliva samples used for RNA RT-LAMP. The logarithm of the viral load was then fitted to the  $C_T$  values for both methods using linear regression followed by converting the  $C_T$  values to viral load based on which method had been used to evaluate the samples. For the remaining samples ( $n = 56$ ) that utilised one of the other two RT-qPCR methods for which viral load was not standardised against a  $C_T$  value, the conversion derived from the

267 CerTest VIASURE SARS-CoV-2 real time PCR kit dilution series was applied, the assumption that the *N* gene  
268  $C_T$  values are the most similar<sup>21–23</sup>.

269 For the CerTest VIASURE SARS-CoV-2 real time PCR kit, the following relationship between log viral load  
270 and  $C_T$  value was applied:

$$271 \log_{10} V = (45.257 - C_T) / 3.523$$

272 and similarly, for the Corman *et al* RT-qPCR assay:

$$273 \log_{10} V = (45.806 - C_T) / 3.717$$

274 where *V* represents the viral load in copies/ml.

275 Viral load was grouped according to the following categories (in copies/ml): <10<sup>3</sup>, 10<sup>3</sup>-10<sup>4</sup>, 10<sup>4</sup>-10<sup>5</sup>, 10<sup>5</sup>-  
276 10<sup>6</sup>, 10<sup>6</sup>-10<sup>7</sup> and >10<sup>7</sup> then the diagnostic sensitivity was calculated according to viral load group with  
277 associated Clopper-Pearson 95% confidence intervals.

278 The site meta-analysis was produced using R 3.5.3. Confusion matrices, sensitivity, specificity, sensitivity  
279 as a function of viral load calculations, and the production of scatter graphs showing the relationship  
280 between RT-LAMP results and  $C_T$  were performed using Python 3.8.6.

281

## 282 Results

### 283 Optimisation of sample preparation conditions

284 Heat inactivation experiments demonstrated that SARS-CoV-2 was completely inactivated by heating at  
 285 60°C (20 min plus) or ≥70°C (after 2, 5 or 10 min) (Supplemental Table S1). Importantly optimised RapiLyse  
 286 Sample Lysis Buffer did not inactivate live virus on its own without a heat step. Further, inactivation at  
 287 56°C was not 100% effective at shorter incubation times, and additionally showed a loss in sensitivity  
 288 following a 4 x 2-fold dilution (Supplemental Table S2, P07102) at 10 and 30 minutes. Following  
 289 optimisation of heat inactivation of live virus, pre-treatment of samples was assessed to determine any  
 290 impact of pre-treatment on assay sensitivity. Interestingly, a pre-treatment 70°C for 5 mins carried out  
 291 on spiked samples prior to the proposed direct RT-LAMP assay had no effect on subsequent LAMP or PCR  
 292 results. It recommended that even if a pre-treatment is effective in inactivating the virus that downstream  
 293 processes are carried out in UV hoods or with effective air-flow management to prevent cross  
 294 contamination of the direct RT-LAMP assay. Comparison of Betapropiolactone (BPL) inactivated virus and  
 295 live virus demonstrated that BPL inactivation has resulted in lower sensitivity of detection using direct RT-  
 296 LAMP. BPL inactivated virus is therefore not an ideal substitute for live virus in spiking experiments. Any  
 297 conclusions on assay sensitivity or performance have consequently been drawn from experiments on  
 298 spiking of live virus in TCSN or saliva carried out in containment. Spiking of live virus into pooled saliva has  
 299 demonstrated that direct detection by RT-LAMP is possible in samples that give a C<sub>T</sub> below 25/26 with  
 300 extraction and PCR.

### 301 RNA RT-LAMP

302 VTM from 12,619 NP/OP swabs were assayed. 265 swab samples were from known symptomatic  
 303 individuals and 2073 swab samples were from known asymptomatic individuals. The clinical status of the  
 304 remaining samples (n= 10,281) was unknown.

305 12,521 neat saliva samples were assayed, none of which were from known symptomatic individuals.  
 306 12,365 of these samples were from known asymptomatic individuals. The clinical status of the remaining  
 307 saliva samples (n= 156) was unknown.

### 308 Direct RT-LAMP

309 VTM from 559 NP/OP swabs were assayed. 170 swab samples were from known symptomatic individuals  
 310 and 310 samples were from known asymptomatic individuals and the clinical status of the remaining swab  
 311 samples (n= 79) was unknown.

312 86,760 neat saliva samples were assayed. 93 samples were from known symptomatic individuals and  
 313 86,593 samples were from known asymptomatic individuals. The clinical status of the remaining samples

(n= 74) was unknown. In addition, 10 separate longitudinal daily saliva samples were provided from one individual as a time course from development of symptoms to three days post resolution of symptoms.

#### **RNA RT-LAMP on NP/OP swabs**

A total of 12,619 swab samples were assayed by RNA RT-LAMP, of which 254 were RT-qPCR positive and 12,365 were RT-qPCR negative. RNA RT-LAMP detected 244 of the 254 positives (Figure 1 and Table 1). Only one of the 12,365 samples negative by RT-qPCR was positive by RNA RT-LAMP. 588 samples were tested in duplicate and 12,031 were tested as single replicates. Of those samples tested in duplicate seven were detected by RNA RT-LAMP in only a single replicate ( $C_T$ s 27.00, 32.66, 33.14, 33.16, 34.07, 35.05, and 37.20 all of these had received at least one freeze thaw before analysis. Overall diagnostic sensitivity (DSe) was 96.06% (95% CI 92.88-98.12) and specificity (DSp) 99.99% (95% CI 99.95-100.00), which is corrected to DSe 95.98% (95% CI 92.70-97.83) and DSp 99.99% (95% CI 99.94-100.00) after site meta-analysis. Diagnostic sensitivity of samples with a  $C_T \leq 25$  (n= 123) was 100.00% (95% CI 96.76-100.00) and specificity 99.99% (95% CI 99.95-100.00), and of samples with a  $C_T \leq 33$  (n=180) was 98.65% (95% CI 96.10-99.72) and specificity 99.99% (95% CI 99.95-100.00).

#### **Direct RT-LAMP on NP/OP swabs**

559 swab samples were assayed by Direct RT-LAMP of which 199 were RT-qPCR positive and 360 were RT-qPCR negative. Direct RT-LAMP detected 140 of the 199 samples positive by RT-qPCR (Figure 1 and Table 2). 195 samples were tested in duplicate and 364 tested as single replicates. Seven of 195 samples tested in duplicate were positive by Direct RT-LAMP in only one replicate ( $C_T$  27.51, 27.95, 28.15, 28.15, 28.87, 28.92, and 28.95) all these samples had received at least one freeze thaw before analysis. Overall diagnostic sensitivity was 70.35% (95% CI 63.48-76.60) and specificity 100% (95% CI 98.98-100). After correction by site meta-analysis, the DSe is corrected to 67.59% (95% CI 53.71-78.94). Diagnostic sensitivity of samples with a  $C_T \leq 25$  (n= 113) was 100% (95% CI 96.34-100) and specificity 100% (95% CI 98.98-100), and of samples with a  $C_T \leq 33$  (n= 182) was 77.78% (95% CI 70.99-83.62) and specificity 100% (95% CI 98.98-100).

#### **RNA RT-LAMP on saliva**

Saliva samples numbering 12,521 were assayed by RNA RT-LAMP of which 155 were RT-qPCR positive and 12,366 were RT-qPCR negative. RNA RT-LAMP detected 133 of the 155 samples that were positive by RT-qPCR (Figure 1 and Table 3). Only one of the 12,366 samples negative by RT-qPCR was positive by RNA RT-LAMP. 44 samples were tested in duplicate and 12,477 were tested as single replicates. All samples tested in duplicate were positive in both replicates. Overall diagnostic sensitivity was 80.65% (95% CI 73.54-86.54) and specificity 99.99% (95% CI 99.95-100), which is corrected to DSe 79.05% (95% CI 68.87 – 86.55) and DSp 99.99% (95% CI 99.74-100) after site meta-analysis. Diagnostic sensitivity of samples

with a  $C_T \leq 25$  ( $n = 74$ ) was 100% (95% CI 93.73-100) and specificity 99.99% (95% CI 99.95-100), and of samples with a  $C_T \leq 33$  ( $n = 150$ ) was 87.32% (95% CI 80.71-92.31) and specificity 99.95 (95% CI 99.95-100.00).

#### Direct RT-LAMP on saliva

86,760 saliva samples were tested by Direct RT-LAMP of which 247 were RT-qPCR positive and 7,195 were RT-qPCR negative (79,318 were negative on RT-LAMP but were not tested by RT-qPCR) (Figure 1 and Table 4). Direct RT-LAMP detected 209 of the 247 samples positive by RT-qPCR. 83 samples were tested in duplicate and 86,677 were tested as single replicates. Nine of the 83 samples tested in duplicate were negative in one of the duplicates and all these samples had received at least one freeze thaw before analysis ( $C_T$  20.27, 21.28, 22.01, 24.42, 25.85, 27.35, 28.52, and 30.37). Overall diagnostic sensitivity was 84.62% (95% CI 79.50-88.88) and specificity 100% (95% CI 99.72-100). After correction by site meta-analysis, DSe is corrected to 84.24% (95% CI 55.03-95.89). Diagnostic specificity was calculated using only the confirmed RT-qPCR negative samples. Diagnostic sensitivity of samples with a  $C_T \leq 25$  ( $n = 126$ ) was 99.01% (95% CI 94.61-99.97) and specificity 100.00% (95% CI 99.72-100), and of samples with a  $C_T \leq 33$  ( $n = 237$ ) was 87.61% (95% CI 82.69-91.54) and specificity 100% (95% CI 99.72-100).

#### Relationship between cycle threshold ( $C_T$ ) value and time to positivity ( $T_p$ )

The relationship between  $C_T$  value and  $T_p$  was explored with the results shown in Figure 1. Whilst there is a weak linear relationship between  $C_T$  value and  $T_p$  across all methods and sample types, a stronger linear relationship was observed in swab samples with  $R^2 = 0.431$  for RNA RT-LAMP and  $R^2 = 0.462$  for Direct RT-LAMP. There was a notably weaker linear relationship in saliva samples  $R^2 = 0.201$  for RNA RT-LAMP and  $R^2 = 0.204$  for Direct RT-LAMP. For RNA RT-LAMP, there was a notable increase in  $T_p$  variance,  $\sigma_{T_p}^2$ , after  $C_T = 20$  across both sample types. On saliva samples,  $\sigma_{T_p}^2 = 0.81$  for  $C_T \leq 20$ , and  $\sigma_{T_p}^2 = 20.41$  for  $C_T > 20$ ; on swabs samples,  $\sigma_{T_p}^2 = 1.96$  and  $C_T \leq 20$ , and  $\sigma_{T_p}^2 = 15.72$  for  $C_T > 20$ . Given the relationship between  $C_T$  value and viral load, this indicates that  $T_p$  is not a reliable indicator for viral load beyond the  $C_T = 20$  threshold.

#### SARS-CoV-2 viral culture of clinical samples across a $C_T$ range

Although not a large sample size; a negative result via Direct RT-LAMP indicates that the presence of culturable virus is less probable and for samples with a  $C_T > 25$  (RDRP/ORF1ab target) recoverable virus is less likely (Table 5). The sensitivity of 1 PFU/ml of the viral culture assay is presented in Supplemental Table S3. No CPE was observed in the flasks inoculated with 0.1 or 0.01 PFU after the two passes. AVL samples were taken from the flasks at the beginning and end of each passage and the  $C_T$  values of the extracted nucleic acids shown in Supplemental Table S3.

## 379 Individual time course

380 In the time course experiment SARS-CoV-2 RNA was detected from day 5 (at the onset of symptoms) up  
381 to day 12 post suspected initial exposure using Direct RT-LAMP and up to day 13 by RNA RT-LAMP,  
382 encompassing the full six days where symptoms were recorded, Supplemental Table S4.

## 383 Performance of RT-LAMP across viral load groups

384 The sensitivity of the RNA and Direct RT-LAMP assays across viral load groups is shown in Figure 2. For  
385 RNA RT-LAMP, samples which were positive by RT-qPCR containing  $>10^5$  copies/ml were consistently  
386 identified as positive with no samples returning a negative result. Below this copy number, sensitivity is  
387 reduced for both saliva and NP/OP swab samples, reaching ~60% in NP/OP swab samples exclusively with  
388 viral loads  $<10^3$  copies/ml, and an approximately linear drop in sensitivity from 100% to 0% between viral  
389 loads of  $10^5$  and  $10^3$  copies/ml respectively in saliva samples. For Direct RT-LAMP, all but one saliva sample  
390 were detected above  $10^6$  copies/ml. On swab samples, sensitivity is reduced on samples containing below  
391  $<10^5$  copies/ml, dropping from 85% at viral loads of  $10^5$ – $10^6$  copies/ml, to 30% in the  $10^4$ – $10^5$  range. On  
392 saliva samples, sensitivity is reduced in the  $10^4$ – $10^5$  range to a sensitivity of 80% but then reduces further  
393 within the  $10^3$ – $10^4$  range, to 30%.

## 394 Site meta-analysis

395 Site-level confusion matrices, sensitivity, and specificity per method and sample type are shown in Figures  
396 3 and 4. For specificity, heterogeneity between sites was minimal for all combinations of method and  
397 sample type, with the random effects model matching the overall aggregated sample calculation. For  
398 sensitivity, heterogeneity was minimal between sites for RNA RT-LAMP. However, for Direct RT-LAMP,  
399 sensitivity showed significant overall heterogeneity (bivariate model variance:  $\sigma_{se}^2 = 1.817$  on saliva  
400 samples;  $\sigma_{se}^2 = 0.228$  on swab samples). Between-site variations in the viral load of the samples tested  
401 contributed a minority of the heterogeneity, but sensitivity was consistently high in samples with higher  
402 viral loads (i.e.,  $>10^6$  copies/ml, as shown in Figure 2), while being more heterogeneous between sites in  
403 samples with lower viral loads. Sensitivity at lower viral loads was highest in the sites with the most  
404 established testing programmes.

405

## 406 Discussion

407 Testing of human populations for SARS-CoV-2 nucleic acid has been hampered by both logistical (e.g.,  
408 swab availability) and physical (e.g., discomfort from repeat swab testing) constraints. The aim of this  
409 study was to evaluate an optimised sample preparation method, building upon previously published  
410 methods for the extraction-free detection of SARS-CoV-2 by RT-LAMP primarily from saliva<sup>3,19</sup>. The

salivary glands are reported to be early targets of SARS-CoV-2 infection<sup>24</sup>, and studies have demonstrated the detection of high viral loads of SARS-CoV-2 from saliva, similar to those observed from nasopharyngeal/oropharyngeal swabs<sup>15,25–27</sup>. Collection of saliva is non-invasive and does not require a trained individual or specialist consumables for collection of a quality sample. Utilising a non-invasive sampling method should open testing to more individuals who dislike or are unable to tolerate having a nasopharyngeal/oropharyngeal swab taken<sup>28</sup>. Additionally, several studies have demonstrated that SARS-CoV-2 viral RNA could be detected from saliva for a similar duration post onset of clinical signs when compared to combined NP/OP swabs<sup>29–31</sup>, highlighting saliva as a valuable tool for SARS-CoV-2 detection.

Direct detection negates the requirement for RNA extraction<sup>32,33</sup>, for which there has previously been competition for reagents and often requires expensive extraction equipment including liquid handling automation. This extraction-free method decreases turnaround time from sample collection to result. The Direct RT-LAMP method is straight forward and rapid, allowing the test to be performed in a wide range of settings, including near-patient hospital laboratories and pop-up or mobile laboratories. However, previously evaluated extraction-free sample preparation methods using RT-LAMP from saliva samples have demonstrated reduced sensitivity<sup>3,19</sup>, likely due to the inhibitory factors found within saliva that may affect molecular tests such as RT-LAMP and RT-qPCR<sup>34,35</sup>. The simple sample preparation method evaluated in the study aimed to improve upon these methods by utilising the addition of a novel proprietary reagent, RapiLyze®, designed to neutralize common sample inhibitors. A subsequent heat step of 98°C for two minutes prior to addition to the RT-LAMP master mix renders SARS-CoV-2 inactive as confirmed by infectivity analysis using live virus inactivation studies (Supplemental Tables S1 and S2). Downstream steps are then able to proceed outside of traditional containment level laboratory settings broadening its clinical utility.

This study utilised high numbers of combined naso/oropharyngeal swabs (n= 559) and saliva samples (n = 86,760) for the evaluation of this novel sample preparation method in combination with the Direct RT-LAMP assay. RNA RT-LAMP was also performed on >25,000 samples for comparison, providing updated values for the performance of the assay reported previously<sup>3,19,36</sup>. Correlation between C<sub>T</sub> value and sample viral copy number has been demonstrated within this and other studies, with lower C<sub>T</sub> values (C<sub>T</sub> <25 and <33) indicating a higher probability that the sample contains recoverable active virus, and consequently the likelihood that the individual may be infectious to others<sup>4,25,37–40</sup>. As a result, the RNA and Direct RT-LAMP assays were compared with RT-qPCR results in groups with three different C<sub>T</sub> cut-off values: <45, <33 and <25. This was completed so that the performance of the assays in different clinical scenarios (use case) could be determined: (i) C<sub>T</sub> <45: does the RT-LAMP assay (either RNA or Direct) compare with RT-qPCR for all reportable C<sub>T</sub> values?; (ii) C<sub>T</sub> <33: can the RT-LAMP assay detect those individuals that have a medium-high levels of viral RNA in their specimens, with an *ORF1ab* target being



analogous with viral copy number because it is exclusively a genomic target<sup>22</sup>; and (iii)  $C_T < 25$ : can the RT-LAMP assay detect those individuals that have a high level of viral RNA in their specimens?

Diagnostic sensitivity for RNA RT-LAMP on swab and saliva samples was improved when compared to a previous report utilising this method<sup>3</sup>, with values of >96% and >80%, respectively when considering all  $C_T$  values, and 100% for both sample types when considering  $C_T < 25$  with these samples having a high probability of containing replicating virus for over 24,000 samples tested. Direct RT-LAMP sensitivity on swab samples was also improved from the previous method with 100% sensitivity for  $C_T < 25$ , 77.78% for  $C_T < 33$  and 70.35% for  $C_T < 45$  across 559 samples used for this evaluation. In contrast, sensitivity for Direct RT-LAMP on saliva was in general higher than that determined for swabs ( $C_T < 33 = 87.61\%$ ,  $C_T < 45 = 84.62\%$ ), apart from the group with  $C_T$  values below <25, which had a reported sensitivity of 99.01%. These results support previous reports which demonstrate comparable performance when comparing paired swabs and saliva samples<sup>41,42</sup>, and that one sample type is not superior to the other. Interestingly, the diagnostic sensitivity for RNA and Direct RT-LAMP for saliva samples was almost equivalent (80.65% and 84.62%, respectively) suggesting that RNA extraction may not even be required when performing testing on saliva samples. Direct RT-LAMP also demonstrates a higher sensitivity than a wide variety of lateral flow tests (LFTs) in the  $C_T < 25$ ,  $C_T \geq 25$  and overall categories, with the overall sensitivity of Direct RT-LAMP on saliva samples achieving a higher overall sensitivity than 94 out of 96 LFTs previously evaluated<sup>43</sup>. We found that the correlation between PCR  $C_T$  value and the Direct RT-LAMP Tp was weaker for saliva than for swabs, which may reflect the PCR  $C_T$  value being from a naso-pharyngeal swab and recognised time course differences between initial viral infection of the salivary glands and later infection of the respiratory tract<sup>26,30</sup>.

Previous studies have described the importance of identifying asymptomatic individuals, particularly those with high viral loads<sup>28,44–48</sup>. The ability of the Direct RT-LAMP assay to reliably detect individuals with medium-high viral loads in a simple to collect, non-invasive sampling process highlights the suitability of this assay for both symptomatic and asymptomatic population screening. This is particularly important in healthcare and care home staff where the use of asymptomatic COVID-19 screening would reduce the risk of onward transmission of SARS-CoV-2, consequently maintaining NHS capacity and Social Care capacity and more importantly, reducing the risk to vulnerable individuals present within those environments<sup>36</sup>.

It is important to note that when designing surveillance strategies for asymptomatic infection testing as an intervention to reduce transmission, frequency of testing and result turnaround time may be considered more significant than diagnostic sensitivity<sup>49</sup>. ‘Gold standard’ tests with high sensitivity such as RT-qPCR generally need to be performed in centralised testing facilities, often resulting in increased reporting times, leading to a less effective control of viral transmission<sup>49</sup>. In contrast, point of care tests

such as Lateral flow tests (LFT)<sup>50,43</sup> or those requiring only a basic/mobile laboratory set-up such as Direct RT-LAMP, which have the ability to produce rapid results, can be performed frequently e.g., daily or multiple times per week. Consequently, the likelihood of sampling an individual when their viral load is highest as seen in the early, often pre-symptomatic stages of infection increases, maximising the probability of rapidly detecting infectious cases, allowing prompt isolation. In this use case sampling and testing frequency using a rapid assay with suitable accuracy in detection of medium-high viral loads, but not necessarily optimal sensitivity over the whole range including low to very low viral loads, is desirable or necessary<sup>49,51</sup>. Frequent on-site testing of asymptomatic NHS healthcare workers using Direct RT-LAMP has been successfully implemented in the pilot study described here; and continues to be utilised. Direct-RT-LAMP has also been used in a mass community based pilot in school and higher education settings<sup>36</sup>, to identify those individuals who may have been missed when surveillance relies only on symptomatic individuals coming forward for testing. With the use of mobile or pop-up laboratories, Direct RT-LAMP could also be used for risk-based mass testing, for example, targeting specific geographical areas or vulnerable groups. The potential also exists for lyophilisation of the Direct RT-LAMP reagents reported in other studies<sup>52,53</sup>, which would minimise the necessity for trained personnel by reducing pipetting steps and the requirement for a cold chain, allowing greater capacity of the assay in multi-use case scenarios including point-of-care and in low- and middle-income countries (LMICs).

Several experiments typical of a diagnostic performance evaluation were not performed as part of this study, as they had been performed and reported previously. This included both analytical specificity, which when tested against a panel of respiratory pathogens causing indistinguishable clinical signs to COVID-19, demonstrated a high level of analytical specificity (100% in this case)<sup>3</sup> and analytical sensitivity of the Direct RT-LAMP, which is reported to detect 1000 cp/ml<sup>3,36,41</sup>. Additionally, the RNA and Direct RT-LAMP assays evaluated as part of this study have been shown to reliably detect the emerging variants of concern (VOC) including the B.1.1.7 alpha variant, the 501Y.V2 beta variant, the P1 gamma variant and the new rapidly spreading B.1.617.2 delta variant<sup>54,55</sup> (<https://www.gov.uk/government/collections/news-sars-cov-2-variant> (accessed June, 2021). The emergence of further VOC could lead to a criticism of the RT-LAMP assay due its reliance on a single target, *ORF1ab*, where mutations in the target region in a sample could lead to false negatives. For RT-qPCR this has been observed during the current pandemic<sup>56-58</sup> where at least a dual target assay is recommended<sup>59</sup>. However, this is less likely to occur for the RT-LAMP assay used in this pilot evaluation. Firstly, due to the multiple sets of primer pairs utilised, three pairs, with two pairs within the target region. This builds in redundancy to mutation not unlike a duplex RT-qPCR. Secondly, the ORF1ab region is highly conserved and crucial for viral replication and fitness in SARS-CoV-2. As a result, these regions are well maintained using a proofreading system via the nsp14 protein<sup>60</sup> resulting in a more stable genome compared to many other RNA viruses.

The authors highlight the importance of incorporating an inhibition control into the next iteration of the RT-LAMP assays. Although the paired RT-LAMP and RT-qPCR data from this study show a good correlation and any false negative results were likely due to the analytical sensitivity of the RT-LAMP assay, not sample driven inhibition. To this end, a control primer set by OptiGene Ltd was evaluated (PS-0010), targeting the human ribosomal protein LO gene. Preliminary analysis of the inhibition control primers showed consistent detection across 279 saliva and 381 combined naso/oropharyngeal swab samples using both RNA and Direct RT-LAMP (manuscript in preparation). Incorporation of this inhibition control into the RT-LAMP assays would alleviate a potential limitation of the current assays and further support quality assurance for use within a clinical diagnostic setting. One further limitation to LAMP assays is the potential for contamination from assay product which can be significant. LAMP assays produce vast amounts which can persist in the environment not only causing potential false positive results in subsequent testing but also anomalous results in laboratory workers who are part of a SARS-CoV-2 testing programme<sup>61</sup>. Therefore, it is crucial that appropriate waste streams are in place to mitigate this risk.

This study demonstrated high sensitivity and specificity for a novel sample preparation method used for SARS-CoV-2 Direct RT-LAMP, particularly in samples from which the individual would likely be considered infectious, highlighting the usefulness of saliva as a simple to collect, non-invasive sample type. The highly sensitive RNA RT-LAMP assay provides a rapid alternative with a reliance on differing reagents and equipment to RT-qPCR testing, thus providing additional diagnostic capacity and redundancy through diversity. Direct RT-LAMP may complement existing surveillance tools for SARS-CoV-2 testing including other point-of-care and laboratory-based diagnostics and is applicable to a variety of clinical scenarios, such as frequent, interval-based testing of asymptomatic individuals that may be missed when reliance is on symptomatic testing alone. However, care should be taken when considering frequency of testing, messaging around the role and interpretation of asymptomatic rapid tests, integration of data storage and access, and the challenges faced when scaling up surveillance to large populations.

The role out of a new testing strategy can often throw up interesting and unexpected experiences. These collective experiences and lessons learnt from setting up an NHS asymptomatic staff testing programme using Direct RT-LAMP will be shared in a future publication.

## Conclusions

Rapid diagnostic testing at scale to identify and isolate symptomatic and asymptomatic individuals potentially transmitting infectious SARS-CoV-2 is an essential part of the response to the COVID-19 pandemic. RT-LAMP on both extracted RNA and directly on crude samples potentially provides faster turnaround times than reverse-transcriptase quantitative real-time PCR testing, with a higher sensitivity and specificity than antigen lateral flow devices. Increasing evidence points to potential benefits of SARS-

547 CoV-2 testing using saliva rather than nasopharyngeal/oropharyngeal swabs, therefore a multi-site  
548 evaluation of an improved simple sample preparation method for Direct SARS-CoV-2 RT-LAMP was  
549 undertaken. This study demonstrated that the RNA RT-LAMP assay has high sensitivity and specificity,  
550 providing a rapid alternative to RT-qPCR testing with a reliance on differing reagents and equipment. The  
551 simple SARS-CoV-2 Direct RT-LAMP preparation method also demonstrated high sensitivity and specificity  
552 for detecting SARS-CoV-2 in saliva and naso/oropharyngeal swabs from asymptomatic and symptomatic  
553 individuals, notably in saliva samples from which the individual would likely be considered infectious. The  
554 findings highlight the usefulness of saliva as a simple to collect, non-invasive sample type, potentially  
555 applicable for interval-based testing of asymptomatic individuals.

556

557

558

## References

1. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, Akdis C, Gao Y. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy Eur J Allergy Clin Immunol*, 2020, 75:1730–41
2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DGJC, Haagmans BL, Van Der Veer B, Van Den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*, 2020, 25:23–30
3. Fowler VL, Armson B, Gonzales JL, Wise EL, Howson ELA, Vincent-Mistiaen Z, Fouch S, Maltby CJ, Gripon S, Munro S, Jones L, Holmes T, Tillyer C, Elwell J, Sowood A, de Peyer O, Dixon S, Hatcher T, Patrick H, Laxman S, Walsh C, Andreou M, Morant N, Clark D, Moore N, Houghton R, Cortes NJ, Kidd SP. A highly effective reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for the rapid detection of SARS-CoV-2 infection. *J Infect*, 2020, 82:117–25
4. Moreira VM, Mascarenhas P, Machado V, Botelho J, Mendes JJ, Taveira N, Almeida MG. Diagnosis of SARS-Cov-2 Infection by RT-PCR Using Specimens Other Than Naso- and Oropharyngeal Swabs: A Systematic Review and Meta-Analysis Vânia. *Diagnostics*, 2021, 11
5. de Paula Eduardo F, Bezinelli LM, de Araujo CAR, Moraes JVV, Birbrair A, Pinho JRR, Hamerschlak N, Al-Hashimi I, Heller D. Self-collected unstimulated saliva, oral swab, and nasopharyngeal swab specimens in the detection of SARS-CoV-2. *Clin Oral Investig*, 2021. <https://doi.org/10.1007/s00784-021-04129-7>
6. Kuo A, Teo J, Choudhury Y, Tan IB, Cher CY, Chew SH, Wan ZY, Tim L, Cheng E, Lin L, Oon E, Tan MH. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. *Sci Rep*, 2021, 11:3134
7. Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF, Casanovas-Massana A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M, Nelson A, Fournier J, Bermejo S, Campbell M, Datta R, Cruz CSD, Farhadian SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB, Wyllie AL. Stability of SARS-CoV-2 RNA in nonsupplemented saliva. *Emerg Infect Dis*, 2021, 27:1146–50
8. Matic N, Stefanovic A, Leung V, Lawson T, Ritchie G, Li L, Champagne S, Romney MG, Lowe CF. Practical challenges to the clinical implementation of saliva for SARS-CoV-2 detection. *Eur J Clin Microbiol Infect Dis*, 2021, 40:447–50
9. Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F, Piechocka-trocha A, Atyeo C, Fischinger S, Chan A, Flaherty KT, Hall K, Dougan M, Ryan ET, Gillespie E, Chishti R, Li Y, Jilg N, Hanidziar D, Baron RM, Baden L, Tsibris AM, Armstrong KA, Kuritzkes DR, Alter G, Walker BD, Yu X, Li JZ, Consortium M. SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat Commun*, 2020, 11:5493

- 595 10. Borghi E, Massa V, Zuccotti G, Wyllie AL. Testing Saliva to Reveal the Submerged Cases of the  
596 COVID-19 Iceberg. *Front Microbiol*, 2021, 12:10–2
- 597 11. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM, Scholar G. Performance of Saliva,  
598 Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a Systematic  
599 Review and Meta-analysis, 2021:1–17
- 600 12. Wong SCY, Tse H, Siu HK, Kwong TS, Chu MY, Yat F, Yau S, Yu I, Cheung Y, Wing C, Tse S, Poon KC,  
601 Cheung KC, Wu TC, Wai J, Chan M, Cheuk W, Lung DC. Posterior Oropharyngeal Saliva for the  
602 Detection of Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS-CoV-2 ), 2020, 2:2939–46
- 603 13. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, Fukumoto T, Sato K, Oguri S, Taki K,  
604 Senjo H, Sugita J, Hayasaka K, Konno S, Nishida M, Teshima T. Comparison of SARS-CoV-2  
605 detection in nasopharyngeal swab and saliva. *J Infect*, 2020, 81:e145–7
- 606 14. Aydin S, Benk IG, Geckil AA. May viral load detected in saliva in the early stages of infection be a  
607 prognostic indicator in COVID-19 patients? *J Virol Methods*, 2021, 294
- 608 15. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. *J Infect*,  
609 2020, 81:e48–50
- 610 16. Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, Carcano G, Ageno W, Gambarini C, Maffioli L,  
611 Saverio S Di, Gasperina DD, Genoni AP, Premi E, Donati S, Azzolini C, Grandi AM, Dentali F,  
612 Tangianu F, Sessa F, Maurino V, Tettamanti L, Siracusa C, Vigezzi A, Monti E, Iori V, Iovino D, Ietto  
613 G, Grossi PA, Tagliabue A, Fasano M. Rapid Salivary Test suitable for a mass screening program to  
614 detect SARS-CoV-2: A diagnostic accuracy study. *J Infect*, 2020, 81:e75–8
- 615 17. Yokota I, Shane PY, Okada K, Unoki Y, Yang Y, Inao T, Sakamaki K, Iwasaki S, Hayasaka K, Sugita J,  
616 Nishida M, Fujisawa S, Teshima T. Mass Screening of Asymptomatic Persons for Severe Acute  
617 Respiratory Syndrome Coronavirus 2 Using Saliva. *Clin Infect Dis*, 2021, 73:e559–65
- 618 18. Masse S, Bonnet C, Vilcu AM, Benamar H, Swital M, van der Werf S, Carrat F, Hanslik T, Blanchon  
619 T, Falchi A. Are posterior oropharyngeal saliva specimens an acceptable alternative to  
620 nasopharyngeal sampling for the monitoring of sars-cov-2 in primary-care settings? *Viruses*,  
621 2021, 13:1–11
- 622 19. Howson ELA, Kidd SP, Armson B, Goring A, Sawyer J, Cassar C, Cross D, Lewis T, Hockey J, Rivers  
623 S, Cawthraw S, Banyard A, Anderson P, Rahou S, Andreou M, Morant N, Clark D, Walsh C, Laxman  
624 S, Houghton R, Slater-Jefferies J, Costello P, Brown I, Cortes N, Godfrey KM, Fowler VL.  
625 Preliminary optimisation of a simplified sample preparation method to permit direct detection of  
626 SARS-CoV-2 within saliva samples using reverse-transcription loop-mediated isothermal  
627 amplification (RT-LAMP). *J Virol Methods*, 2021, 289
- 628 20. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis  
629 of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J*  
630 *Clin Epidemiol*, 2005, 58:982–90



- 631 21. Bhargava A. Dynamic aspects of ORF1ab and N RNA cycle threshold values among COVID-19  
632 patients in China. *Infect Genet Evol*, 2021, 87:104657
- 633 22. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic  
634 samples are not an indicator of active replication. *Nat Commun*, 2020, 11:6059
- 635 23. Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, Xue Y. Clinical features and dynamics of viral load in  
636 imported and non-imported patients with COVID-19. *Int J Infect Dis*, 2020, 94:68–71
- 637 24. Huang N, Pérez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the oral  
638 cavity and saliva. *Nat Med*, 2021, 27:892–903
- 639 25. To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, Yip CCY, Cai JP, Chan JMC, Chik TSH,  
640 Lau DPL, Choi CYC, Chen LL, Chan WM, Chan KH, Ip JD, Ng ACK, Poon RWS, Luo CT, Cheng VCC,  
641 Chan JFW, Hung IFN, Chen Z, Chen H, Yuen KY. Temporal profiles of viral load in posterior  
642 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an  
643 observational cohort study. *Lancet Infect Dis*, 2020, 20:565–74
- 644 26. Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard sample for SARS-  
645 CoV-2 detection. *Lancet Respir Med*, 2021, 2600:19–21
- 646 27. Savelle ES, Winnett A, Romano AE, Porter MK, Shelby N, Akana R, Ji J. Quantitative SARS-CoV-2  
647 viral-load curves in paired saliva and nasal swabs inform appropriate respiratory sampling site  
648 and analytical test sensitivity required for earliest viral detection. *MedRxiv*, 2021:1–37
- 649 28. Yang Q, Saldi TK, Gonzales PK, Lasda E, Decker CJ, Tat KL, Fink MR, Hager CR, Davis JC, Ozeroff  
650 CD, Muhlrud D, Clark SK, Fattor WT, Meyerson NR, Paige CL, Gilchrist AR, Barbachano-Guerrero  
651 A, Worden-Sapper ER, Wu SS, Brisson GR, McQueen MB, Dowell RD, Leinwand L, Parker R,  
652 Sawyer SL. Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in  
653 communities. *Proc Natl Acad Sci U S A*, 2021, 118:1–6
- 654 29. Uwamino Y, Nagata M, Aoki W, Fujimori Y, Nakagawa T, Yokota H, Sakai-Tagawa Y, Iwatsuki-  
655 Horimoto K, Shiraki T, Uchida S, Uno S, Kabata H, Ikemura S, Kamata H, Ishii M, Fukunaga K,  
656 Kawaoka Y, Hasegawa N, Murata M. Accuracy and stability of saliva as a sample for reverse  
657 transcription PCR detection of SARS-CoV-2. *J Clin Pathol*, 2021, 74:67–8
- 658 30. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al.  
659 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *N Engl J Med*, 2020,  
660 383:1283–6
- 661 31. Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, et al. SalivaDirect: A  
662 simplified and flexible platform to enhance SARS-CoV-2 testing capacity. *Med*, 2021, 2:263-  
663 280.e6
- 664 32. Buck MD, Poirier EZ, Cardoso A, Frederico B, Canton J, Barrell S, et al. SARS-CoV-2 detection by a  
665 clinical diagnostic RT-LAMP assay. *Wellcome Open Res*, 2021, 6:9
- 666 33. Kellner MJ, Matl M, Ross JJ, Schnabl J, Handler D, Heinen R, Schaeffer J, Hufnagl P, Indra A,



667 Dekens MP, Fritsche-Polanz R, Födinger M, Zuber J, Allerberger F, Pauli A, Brennecke J, BioCenter  
668 Program V. Head-to-head comparison of direct-input RT-PCR and RT-LAMP against RT-qPCR on  
669 extracted RNA for rapid SARS-CoV-2 diagnostics. MedRxiv, 2021:2021.01.19.21250079

670 34. Ochert AS, Boulter AW, Birnbaum W, Johnson NW, Teo CG. Inhibitory effect of salivary fluids on  
671 PCR: Potency and removal. PCR Methods Appl, 1994, 3:365–8

672 35. Wilson IG. Inhibition and facilitation of nucleic acid amplification. Appl Environ Microbiol, 1997,  
673 63:3741–51

674 36. Department of Health and Social Care. Rapid evaluation of OptiGene RT-LAMP assay (direct and  
675 RNA formats). Department of Health and Social Care. United Kingdom. 2020

676 37. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P, Raoult D. Viral  
677 RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2  
678 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis, 2020, 39:1059–61

679 38. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A,  
680 Schiffman Z, Doan K, Bastien N, Li Y, van Caesele PG, Poliquin G. Predicting infectious severe  
681 acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis, 2020,  
682 71:2663–6

683 39. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC,  
684 Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirgmaier K,  
685 Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019.  
686 Nature, 2020, 581:465–9

687 40. Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, Marks M, Guedj J.  
688 Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. Elife, 2021,  
689 10:e69302

690 41. Fowler DV, Douglas DA, Godfrey PK, Williams PA, Beggs PA, Kidd S, Cortes DN, Wilcox PM, Davies  
691 DK, Smith M, Hill PDS. Critical evaluation of the methodology used by Wilson-Davies et al., (2020)  
692 entitled “Concerning the Optigene Direct LAMP assay, and it’s use in at-risk groups and hospital  
693 staff.” J Infect, 2021, 82:282–327

694 42. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir SM. Self-collected  
695 anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal swabs  
696 for the molecular detection of SARS-CoV-2. J Clin Microbiol, 2020, 58:e01824-20

697 43. Scheiblaue H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, Zwirgmaier K, Lange  
698 C, Emmerich P, Müller M, Knauer O, Nübling CM. Comparative sensitivity evaluation for 122 CE-  
699 marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021.  
700 Eurosurveillance, 2021, 26:1–13

701 44. Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection:  
702 Invisible yet invincible. Int J Infect Dis, 2020, 100:112–6

- 703 45. Marks M, Millat P, Ouchi D, Roberts C, Alemany A, Corbacho-Monné M, Ubals M, Vall-Mayans M,  
704 G-Beiras C, Prat N, Ara J, Clotet B, Mitjà O. Transmission of COVID-19 in 282 clusters in Catalonia,  
705 Spain: A cohort study. *Lancet Infect Dis*, 2021, 21:6290
- 706 46. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of  
707 asymptomatic COVID-19 and its potential for community transmission: Systematic review and  
708 meta-analysis. *J Assoc Med Microbiol Infect Dis Canada*, 2020, 5:223–34
- 709 47. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, Salanti G, Low N.  
710 Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2  
711 infections: A living systematic review and meta-analysis. *PLoS Med*, 2020, 17:e1003346
- 712 48. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, Slayton RB, Biggerstaff  
713 M, Butler JC. SARS-CoV-2 Transmission from People without COVID-19 Symptoms. *JAMA Netw*  
714 *Open*, 2021, 4:1–8
- 715 49. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, Parker R.  
716 Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv*,  
717 2021, 7:1–11
- 718 50. Lee LYW, Rozmanowski S, Pang M, Charlett A, Anderson C, Hughes GJ, Barnard M, Peto L, Vipond  
719 R, Sienkiewicz A, Hopkins S, Bell J, Crook DW, Gent N, Walker AS, Peto TEA, Eyre DW. SARS-CoV-2  
720 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow  
721 devices to prevent transmission. *Clin Infect Dis*, 2021, May:ciab421
- 722 51. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, Kalinich CC, Jednak S, Ott IM, Vogels  
723 CBF, Wohlgemuth J, Weisberger J, DiFiori J, Anderson DJ, Mancell J, Ho DD, Grubaugh ND, Grad  
724 YH. Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health  
725 strategies. *PLoS Biol*, 2021, 19:1–17
- 726 52. Howson ELA, Armson B, Madi M, Kasanga CJ, Kandusi S, Sallu R, Chepkwony E, Siddle A, Martin P,  
727 Wood J, Mioulet V, King DP, Lembo T, Cleaveland S, Fowler VL. Evaluation of Two Lyophilized  
728 Molecular Assays to Rapidly Detect Foot-and-Mouth Disease Virus Directly from Clinical Samples  
729 in Field Settings. *Transbound Emerg Dis*, 2017, 64:861–71
- 730 53. Armson B, Walsh C, Morant N, Fowler VL, Knowles NJ, Clark D. The development of two field-  
731 ready reverse transcription loop-mediated isothermal amplification assays for the rapid  
732 detection of Seneca Valley virus 1. *Transbound Emerg Dis*, 2019, 66:497–504
- 733 54. Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, Hayward A, Cevik M, Semple C.  
734 NERVTAG note on B.1.1.7 severity. *Sage*, 2021:5–8
- 735 55. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and  
736 rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2)  
737 lineage with multiple spike mutations in South Africa. *MedRxiv*, 2020, 2
- 738 56. Vanaerschot M, Mann SA, Webber JT, Kamm J, Bell SM, Bell J, Hong SN, Nguyen MP, Chan LY,

739 Bhatt KD, Tan M, Detweiler AM, Espinosa A, Wu W, Batson J, Dynerman D, Wadford DA,  
740 Puschnik AS, Neff N, Ah Yong V, Miller S, Ayscue P, Tato CM, Paul S, Kistler AL, DeRisi JL, Crawford  
741 ED. Identification of a Polymorphism in the N Gene of SARS-CoV-2 That Adversely Impacts  
742 Detection by Reverse Transcription-PCR. *J Clin Microbiol*, 2020, 59:e02369-20

743 57. Hasan MR, Sundararaju S, Manickam C, Mirza F, Al-Hail H, Lorenz S, Tang P. A Novel Point  
744 Mutation in the N Gene of SARS-CoV-2 May Affect the Detection of the Virus by Reverse  
745 Transcription-Quantitative PCR. *J Clin Microbiol*, 2021, 59:e03278-20

746 58. Artesi M, Bontems S, Göbbels P, Franckh M, Maes P, Boreux R, Meex C, Melin P, Hayette M-P,  
747 Bours V, Durkin K. A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with  
748 Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-  
749 Target Diagnostic Assay. *J Clin Microbiol*, 2020, 58:e01598-20

750 59. Wang R, Hozumi Y, Yin C, Wei G-W. Mutations on COVID-19 diagnostic targets. *Genomics*, 2020,  
751 112:5204–13

752 60. Rausch JW, Capoferri AA, Katusiime MG, Patro SC, Kearney MF. Low genetic diversity may be an  
753 Achilles heel of SARS-CoV-2. *Proc Natl Acad Sci*, 2020, 117:24614 LP – 24616

754 61. Robinson-McCarthy LR, Mijalis AJ, Filsinger GT, de Puig H, Donghia NM, Schaus TE, Rasmussen  
755 RA, Ferreira R, Lunshof JE, Chao G, Ter-Ovanesyan D, Dodd O, Kuru E, Sesay AM, Rainbow J,  
756 Pawlowski AC, Wannier TM, Angenent-Mari NM, Najjar D, Yin P, Ingber DE, Tam JM, Church GM.  
757 Laboratory-Generated DNA Can Cause Anomalous Pathogen Diagnostic Test Results. *Microbiol*  
758 *Spectr*, 2021, 9:1–9

759  
760

## Tables

**Table 1.** Diagnostic sensitivity and specificity of RNA RT-LAMP on swabs compared with RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;45 Swab</b>	RNA RT-LAMP Pos	244 <sup>†</sup>	1	245	<b>DSe</b>	96.06	92.88-98.12
	RNA RT-LAMP Neg	10	12364	12374	<b>DSp</b>	99.99	99.95-100
	Total	254	12365				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;33 Swab</b>	RNA RT-LAMP Pos	219	1	220	<b>DSe</b>	98.95	96.10-99.72
	RNA RT-LAMP Neg	3	12364	12367	<b>DSp</b>	99.9	99.95-100
	Total	222	12365				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;25 Swab</b>	RNA RT-LAMP Pos	112	1	113	<b>DSe</b>	100	96.76-100
	RNA RT-LAMP Neg	0	12364	12364	<b>DSp</b>	99.9	99.95-100
	Total	112	12365				

<sup>†</sup>Five samples included in this number were positive by RT-qPCR but did not have an associated C<sub>T</sub> value due to being assayed on a platform that did not produce a C<sub>T</sub> value. DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

**Table 2.** Diagnostic sensitivity and specificity of Direct RT-LAMP on swabs compared to RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;45 Swab</b>	Direct RT-LAMP Pos	140	0	140	<b>DSe</b>	70.35	63.48-76.60
	Direct RT-LAMP Neg	59	360	419	<b>DSp</b>	100	98.98-100
	Total	199	360				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;33 Swab</b>	Direct RT-LAMP Pos	140	0	140	<b>DSe</b>	77.78	70.99-83.62
	Direct RT-LAMP Neg	40	360	400	<b>DSp</b>	100	98.98-100
	Total	180	360				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;25 Swab</b>	Direct RT-LAMP Pos	99	0	99	<b>DSe</b>	100	96.34-100
	Direct RT-LAMP Neg	0	360	360	<b>DSp</b>	100	98.98-100
	Total	99	360				

DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

773

774 **Table 3.** Diagnostic sensitivity and specificity of RNA RT-LAMP on saliva compared to RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;45 Saliva</b>	RNA RT-LAMP Pos	125	1	126	<b>DSe</b>	80.65	73.54-86.54
	RNA RT-LAMP Neg	30	12365	12395	<b>DSp</b>	99.99	99.95-100
	Total	155	12366				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;33 Saliva</b>	RNA RT-LAMP Pos	124	1	125	<b>DSe</b>	87.32	80.71-92.31
	RNA RT-LAMP Neg	18	12365	12383	<b>DSp</b>	99.99	99.95-100
	Total	142	12366				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;25 Saliva</b>	RNA RT-LAMP Pos	57	1	58	<b>DSe</b>	100	93.73-100
	RNA RT-LAMP Neg	0	12365	12365	<b>DSp</b>	99.99	99.95-100
	Total	57	12366				

775 DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

776

777 **Table 4.** Diagnostic sensitivity and specificity of Direct RT-LAMP on saliva compared to RT-qPCR.

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub>&lt;45 Saliva</b>	Direct RT-LAMP Pos	209	0	209	<b>DSe</b>	84.62	79.50-88.88
	Direct RT-LAMP Neg	38	7195*	7233	<b>DSp</b>	100.00	99.95-100.00
	Total	247	7195				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;33 Saliva</b>	Direct RT-LAMP Pos	205	0	205	<b>DSe</b>	87.61	82.69-91.54
	Direct RT-LAMP Neg	29	7195*	7224	<b>DSp</b>	100.0	99.95-100.00
	Total	234	7195				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;25 Saliva</b>	Direct RT-LAMP Pos	100	0	100	<b>DSe</b>	99.01	94.61-99.97
	Direct RT-LAMP Neg	1	7195*	7196	<b>DSp</b>	100.0	99.95-100.00
	Total	101	7195				

778 \*85,177 samples were negative on RT-LAMP but only 7,196 were confirmed negative by RT-qPCR. Only those which  
779 were confirmed negative by RT-qPCR were included in the calculations.

780

781

**Table 5.** Viral culture of positive VTM from oro/pharyngeal swabs and assay results.

Sample	Direct RT-LAMP	RNA RT-LAMP	C <sub>T</sub> values for each RT-qPCR assay			CPE
			Genesig RDRP gene	VIASURE	SARS-CoV-2 E gene Sarbeco assay	
				ORF1ab		
1	POS	POS	19.9	18.7	17.8	CPE+
2	POS	POS	21.3	19.9	19.0	CPE+
3	POS	POS	21.6	19.1	18.5	CPE+
4	POS	POS	22.6	20.8	19.8	CPE+
5	POS	POS	22.9	21.6	21.0	CPE+
6	POS	POS	23.7	20.6	20.6	CPE+
7	NEG	POS	-	ND	ND	No CPE
8	NEG	POS	39.2	ND	ND	No CPE
9	NEG	POS	35.2	ND	ND	No CPE
10	NEG	NEG	34.6	ND	ND	No CPE
11	NEG	POS	35.4	ND	ND	No CPE
12	NEG	POS	36.2	ND	ND	No CPE
13	POS	POS	35.8	ND	ND	No CPE
14	POS	POS	34.5	ND	ND	No CPE
15	NEG	POS	35.1	ND	ND	No CPE
16	POS	POS	30.0	ND	ND	No CPE
17	POS	POS	32.3	ND	ND	No CPE
18	NEG	POS	34.6	ND	ND	No CPE
19	POS	POS	31.3	ND	ND	No CPE
20	NEG	POS	30.3	ND	ND	No CPE
21	NEG	POS	30.0	ND	ND	No CPE
22	NEG	POS	31.5	ND	ND	No CPE
23	NEG	POS	30.7	ND	ND	CPE+
24	POS	POS	29.9	ND	ND	No CPE
25	POS	POS	29.4	ND	ND	No CPE
26	NEG	POS	28.2	ND	ND	CPE+

Samples were taken through 3 passages. ND: not done.

## Figure Legends

**Figure 1.** Time to positivity [Tp] in minutes plotted against RT-qPCR Cycle Threshold [C<sub>T</sub>] for each combination of method and sample type. Samples which were negative by RT-qPCR are not shown. Samples which were negative by RT-LAMP are shown with 0 time to positivity. Results of linear ordinary least squared regression are shown for samples which were RT-LAMP positive with the regression line and corresponding 95% confidence interval represented by the blue line and light blue shaded regions respectively.


**Figure 2.** Performance of the RNA RT-LAMP and Direct RT-LAMP assays on both saliva and swab samples according to viral load groupings.

**Figure 3.** Forest plots for Direct RT-LAMP per sample type showing site heterogeneity in sensitivity and specificity, with overall estimates and the resulting expected sensitivity and specificity retrieved from each respective bivariate random effects model.

**Figure 4:** Forest plots for RNA RT-LAMP per sample type showing site heterogeneity in sensitivity and specificity, with overall estimates and the resulting expected sensitivity and specificity retrieved from each respective bivariate random effects model.




815 **Figure 1**



816  
817  
818  
819  
820  
821

822 **Figure 2**




823

824

825 **Figure 3**


### Direct RT-LAMP Saliva

Site	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Animal and Plant Health Agency	144	0	12	5867	0.92 [0.87, 0.96]	1.00 [1.00, 1.00]
Hampshire Hospitals NHS Foundation Trust	42	0	18	527	0.70 [0.57, 0.81]	1.00 [0.99, 1.00]
Institute of Cancer & Genomic Science	16	0	0	52	1.00 [0.79, 1.00]	1.00 [0.93, 1.00]
Manchester University NHS Foundation Trust	7	0	8	749	0.47 [0.21, 0.73]	1.00 [1.00, 1.00]
Overall	209	0	38	7195	0.85 [0.80, 0.89]	1.00 [1.00, 1.00]
Random effects model					0.84 [0.55, 0.96]	1.00 [1.00, 1.00]



### Direct RT-LAMP Swabs


Site	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Division of Virology, Porton Down	7	0	12	0	0.37 [0.16, 0.62]	Not estimatable
Gibraltar Health Authority	31	0	11	11	0.74 [0.58, 0.86]	1.00 [0.72, 1.00]
Hampshire Hospitals NHS Foundation Trust	63	0	19	349	0.77 [0.66, 0.85]	1.00 [0.99, 1.00]
Leeds Teaching Hospitals NHS Trust	39	0	17	0	0.70 [0.56, 0.81]	Not estimatable
Overall	140	0	59	360	0.70 [0.63, 0.77]	1.00 [0.99, 1.00]
Random effects model					0.68 [0.54, 0.79]	1.00 [0.99, 1.00]



832 **Figure 4**

### RNA RT-LAMP Saliva

Site	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Hampshire Hospitals NHS Foundation Trust	78	1	14	3154	0.85 [0.76, 0.91]	1.00 [1.00, 1.00]
Institute of Cancer & Genomic Science	1	0	0	3645	1.00 [0.03, 1.00]	1.00 [1.00, 1.00]
Manchester University NHS Foundation Trust	18	0	9	2371	0.67 [0.46, 0.83]	1.00 [1.00, 1.00]
University Hospital Southampton NHS Foundation Trust	28	0	7	3195	0.80 [0.63, 0.92]	1.00 [1.00, 1.00]
Overall	125	1	30	12365	0.81 [0.74, 0.87]	1.00 [1.00, 1.00]
Random effects model					0.79 [0.69, 0.87]	1.00 [1.00, 1.00]



833


834

835

836

### RNA RT-LAMP Swabs

Site	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Division of Virology, Porton Down	19	0	1	0	0.95 [0.75, 1.00]	Not estimatable
Hampshire Hospitals NHS Foundation Trust	205	1	8	10601	0.96 [0.93, 0.98]	1.00 [1.00, 1.00]
Institute of Cancer & Genomic Science	0	0	0	1459	Not estimatable	1.00 [1.00, 1.00]
Manchester University NHS Foundation Trust	1	0	1	302	0.50 [0.01, 0.99]	1.00 [0.99, 1.00]
University Hospital Southampton NHS Foundation Trust	14	0	0	2	1.00 [0.77, 1.00]	1.00 [0.16, 1.00]
Overall	239	1	10	12364	0.96 [0.93, 0.98]	1.00 [1.00, 1.00]
Random effects model					0.96 [0.93, 0.98]	1.00 [1.00, 1.00]



837

838

# **Supplemental Information**

840

841 **Supplemental Table S1:** Serial dilution of Patient VTM ( $C_T = 19$ ) 1:1 VTM into Lysis Buffer and 98°C heat treatment  
842 without and without heat pre-treatment at 56°C for 10 or 30 minutes.

P07553 ( $C_T = 19$ )	1:2	1:4	1:8	1:16	1:36	1:64	1:128	1:256	1:512	1:1024	1:2048
VTM 1:1 into Lysis + 98°C	D	D	D	D	D	D	D	D	D	D	D
	D	D	D	D	D	D	D	D	D	D	D
56°C 10 mins pre-treat 1:1 VTM into lysis +98°C	D	D	D	D	D	D	D	D	D	D	ND
	D	D	D	D	D	D	D	D	D	D	ND
56°C 30 mins pre-treat 1:1 VTM into lysis +98°C	D	D	D	D	D	D	D	ND	D	ND	ND
	D	D	D	D	D	D	D	D	ND	ND	ND

843 D – RNA Detected, ND – RNA Not Detected, by Direct RT-LAMP.

844

845

846 **Supplemental Table S2** - Serial dilution of Patient VTM ( $C_T$  19.00 to 32.08) 1:1 VTM into Lysis Buffer and 98°C heat  
847 treatment without and without heat pre-treatment at 56°C for 10 or 30 minutes.

Patient VTM	P07553 ( $C_T$ 19)	P01127 ( $C_T$ 23.97)	P07102 ( $C_T$ 32.08)	P07392 ( $C_T$ 24.55)	P01071 ( $C_T$ 20.54)
VTM into 1:1 Lysis + 98°C	D	D	D	D	D
	D	D	D	D	D
56°C 30 mins pre-treat 1:1 VTM into lysis + 98°C	D	D	ND	D	D
	D	D	ND	D	D

848 D – RNA Detected, ND – RNA Not Detected, by Direct RT-LAMP.

849

850

851 **Supplemental Table S3 - Sensitivity of the viral culture assay – 1 PFU/ml**

Number of PFU added to AVL/flask	E Gene RT-PCR assay			Growth (CPE)	
	C <sub>T</sub> value of dilution (AVL)	Baseline Mean C <sub>T</sub> value from flasks	Final Mean C <sub>T</sub> value from flasks	Flask 1	Flask 2
1000	19.64	25.0	12.2	+	+
100	22.65	28.4	11.8	+	+
10	26.00	31.8	11.9	+	+
1	28.73	35.0	12.6	+	+
0.1	32.11	37.6	37.3	-	-
0.01	34.43	39.8	37.7	-	-

852

853

854

855 **Individual time course**

856 **Supplemental Table S4 - RT-LAMP results of time course from symptom onset**

Days post suspected exposure	Direct RT-LAMP			RNA RT-LAMP			RT-qPCR C <sub>T</sub>		Observed Symptoms
	Tp 1	Tp 2	Result	Tp 1	Tp 2	Result	ORF1ab	N	
5	09:18	09:32	POS	11:09	10:50	POS	23.31	26.47	Onset: Sore throat. Blocked nose. Headache. Lack of appetite. Fever.
6	10:32	11:34	POS	10:34	10:40	POS	21.16	24.03	Sore throat. Headache. Restless sleeping. Tired
7	10:19	13:40	POS	11:39	09:59	POS	24.47	27.30	Headache. Restless sleeping. Tired. Loss of smell and taste.
9	09:31	09:14	POS	08:35	09:37	POS	28.55	31.89	Tired. Loss of smell and taste.
11	13:14	11:47	POS	16:44	16:39	POS	26.44	29.06	Tired. Loss of smell and taste.
12	09:10	10:09	POS	12:42	12:01	POS	26.13	29.19	Tired. Improvement in smell and taste.
13	NEG	NEG	NEG	14:06	12:56	POS	28.16	30.62	Significant improvement in all symptoms
14	NEG	NEG	NEG	NEG	NEG	NEG	38.05	40.73	None
16	NEG	NEG	NEG	NEG	NEG	NEG	36.11	NEG	None
17	NEG	NEG	NEG	NEG	NEG	NEG	NEG	NEG	None

857 Time to positivity in minutes [Tp]; Cycle Threshold [C<sub>T</sub>]; Negative [NEG]; positive [POS]

858